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DISEASE RECURRENCE AND REJECTION FOLLOWING LIVER 
TRANSPLANTATION FOR AUTOIMMUNE CHRONIC ACTIVE 
LIVER DISEASE 
HARLAN L. WRIGHT, CHARLES F. Bou-ABBOUD, TAREK HASSANEIN, GEOFFREY D. BLOCK, 
A. JAKE DEMETRIS, THOMAS E. STARZL, AND DAVID H. VAN THIELl 
Departments of Surgery and Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261 
Autoimmune chronic active liver disease (ACALD), a 
major indication for liver transplantation, is associated 
strongly with antigenic determinants HLA-B8 and DR3. 
A retrospective analysis of 43 patients who underwent 
OLTx for putative ACALD and who, as well as their 
tiNue organ donors, were typed, was performed. Dis-
ease recurrence and graft rejection episodes were deter-
mined by chart review and histopathological review of 
all material available. Disease recurrence was histolog-
ically documented in 11 (25.6%) of these 43 cases. Graft 
rejection episodes occurred in 24 (55.8%). All recur-
rences were in recipients of HLA-DR3-negative grafts. 
Nine of the recurrences were in HLA-DR3-positive re-
'Address correspondence to: D. H. Van Thiel, M.D., 3601 Fifth 
Avenue, Falk Clinic 5C, Pittsburgh, PA 15213. 
cipients (odds ratio: 6.14, P<O.03). Two of 11 cue. of 
disease recurrence were in recipients who were HLA-
DR3-negative. Nine of these 11 had received-HLA-
DR3-negative grafts. Rejection occurred in 13 BLA-
BS-positive recipients, 12 of whom received BLA-BS-
negative grafts. Eleven HLA-B8-negative recipients 
experienced at least one rejection episode and 9 of these 
had received HLA-B8-negative grafts. Based upon 
these data we conclude: 1) that recurrence of putative 
ACALD is more likely to occur in HLA-DR3-positive 
recipients of HLA-DR3-negative grafts; (2) that recur-
rences were not seen in recipients of HLA-DR3-poeitive 
grafts; (3) that HLA-B8 status does not affect disease 
recurrence; and (4) that neither the HLA-B8 nor the 
DR3 status of the graft or recipient has an effect on the 
observed frequency of rejection. 
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Autoimmune chronic active liver disease (ACALD)* is known 
to be associated with certain HLA antigenic determinants, 
specifically the class I antigens HLA-A1 and B8 (1) and the 
class II antigen DR3 (2). These antigens are thought to reside 
near an abnormal immune response gene, found on chromo-
some 6, which is in genetic disequilibrium with these particular 
HLA antigens. It is the presence of the abnormal immune 
response gene that predisposes an individual to develop 
ACALD. 
Currently, ACALD is one of the major specific disease indi-
cations for orthotopic liver transplantation. Disease recurrence 
following OLTx for this indication has occurred in at least one 
recipient (3). In this single report, the recipient was HLA-B8 
and HLA-DR3-positive, while the liver donor was negative for 
both of these two antigens. In contradistinction to the situation 
with other organs, HLA typing has not been performed rou-
tinely in clinical OLTx, because several retrospective analyses 
have indicated that the HLA matching is not important in 
determining the long-term survival of either the graft or the 
patient following OLTx (4). 
Because tissue typing of both the donor and the recipient 
has been standard practice at the University of Pittsburgh, it 
was possible to determine whether the presence or absence of 
HLA matching for HLA-B8 and DR3 affects the subsequent 
course in terms of disease recurrence and the frequency of 
rejection episodes. It was anticipated that a donor/recipient 
HLA match for DR3 and possibly for B8 would increase the 
frequency of disease recurrence while simultaneously decreas-
ing the frequency of rejection episodes. 
MATERIALS AND METHODS 
The charts of all patients who were transplanted for putative autoim· 
mune chronic active liver disease from November 1981 through July 
1989 who had a typical disease course, including responsiveness to 
glucocorticoid treatment, absence of all viral markers, and typical 
serological markers for ACALD, were reviewed. The charts of all such 
liver transplant recipients with a minimum duration of posttransplan-
tation follow-up of 10 months were evaluated in detail. A total of 114 
such patients were identified. For 49 of these, the HLA typing data of 
both the donor and the recipient were available. Of these 49, 6 had died 
in the immediate posttransplant period and were excluded from the 
analysis. Two of these 6 died as a result of primary graft dysfunction, 
2 died as a result of a vascular complication, and the remaining 2 died 
as a result of overwhelming sepsis. 
All patients during this period were treated with standard immuno-
suppression consisting of cyclosporine and prednisone_ For the purpose 
of this study, only the data relevant to the first organ graft, when more 
than one graft procedure was performed in a single recipient, were 
reviewed. All pre- and posttranaplant liver biopsies were rereviewed. 
Each of the posttranaplant liver biopsies was performed because of 
either a suspicion of graft rejection or an alteration in liver injury 
parameters and/or an increaae in the aerum bilirubin level. After 
rereview, those biopsies that were considered to be histologically con-
siatent with a diagnosia of a recurrence of autoimmune chronic active 
liver disease were coded u cases of disease recurrence. Cases that were 
identified as showing either acute cellular rejection or chronic rejection 
were coded as cases of rejection. The hiatological diagnosis of rejection 
in each case wu estimated using established using established criteria 
(5,6). Finally, the proportion of cases matched for HLA antigens B8 
and DR3 in the donor and recipient was determined and compared 
with the proportion of cases with the same histologic fmdings but 
without such donor and recipient matching. 
* Abbreviation: ACALD, autoimmune chronic active liver disease. 
Statistical analysi& All results are reported u absolute numbers. The 
true odds ratio was computed. The 95% confidence interval for the true 
odds ratio was calculated by the exact maximum likelihood method. 
Fiaher's exact test was used to examine relationships of disease status 
with HLA markers. A P value le88 than 0.05 was considered to represent 
a significant difference. 
RESULTS 
Eleven cases of disease recurrence were noted in these 43 
patients. All 11 cases of disease recurrence were in recipients 
who received HLA-DR3-negative donor organs (Fig. 1). The 
clinical characteristics of these 11 cases are shown in Table 1. 
All were positive for one or more autoantibodies and had 
hypergammaglobulinemia before and after OLTx at the time 
of disease recurrence dermed histologically. Moreover, as all 
posttransplant liver biopsies were obtained only as indicated 
for clinical reasons, all had abnormal liver enzymes consistent 
with a diagnosis of recurrent chronic active hepatitis. Six 
recipients received HLA-DR3-positive grafts, and no histologic 
evidence for disease recurrence was noted in any. Nine of 20 
HLA-DR3-positive recipients experienced histologic recur-
rence of their chronic active hepatitis. In contrast, only two of 
17 HLA-DR3-negative recipients experienced evidence for dis-
ease recurrence dermed histologically (odds ratio: 6.14, 
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FIGURE 1. Percentage of recipients experiencing disease recurrence 
based upon the HLA-DR3 status of the donor-recipient pairing. 
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TABLE 1. Clinical characteristics of the 11 subjects with recurrent 
ACALD 
A. General characteristics 
Gender 
Age 
CbaracterUtic 
Time posttranaplant when histology 
positive for ACALD 
B. Autoantibody atsUm 
AutoUltibodiea po.itive 
ANA 
Antimicrosomal 
Antithyroglobulin 
Antismooth muscle 
Symptomatic" 
Fivefold elevation of trans-
aminases 
Twofold increase in gamma-
globulin levels 
Pre-OLTx 
6/11 
11/11 
10/11 
8/11 
11/11 
5/11 
11/11 
No. 
All women 
49±3 years 
18±4 months 
POI!t-OLTx 
5/11 
11/11 
9/11 
8/11 
11/11 
8/11 
11/11 
• Symptoms including arthritis, fatigue, and abdominal (hepatic) 
discomfort. 
1 
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P<0.03). All but one of the cases of disease recurrence were in 
recipients of HLA-B8-negative donor organs (Fig. 2). Six of 
these recipients were HLA-B8-positive. Eight patients received 
HLA-B8-positive grafts. Only one of these found to experience 
histologic recurrence. Seven of 21 HLA-B8-positive recipients 
experienced disease recurrence. Four of 22 HLA-B8-negative 
recipients experienced histologic disease recurrence. All had 
received HLA-B8-negative grafts. 
Rejection episodes occurred in two of the six recipients that 
received HLA-DR3-positive donor grafts and in 22 of 37 who 
received HLA-DR3-negative grafts (Fig. 3). Thirteen of 24 
HLA-DR3-positive recipients experienced at least one episode 
of rejection. All of these had received HLA-DR3-negative donor 
organs. Four of the recipients had HLA-DR3-positive grafts 
and none of them rejected. Eleven of 19 HLA-DR3-negative 
recipients experienced at least one episode of rejection; 9 of 
these 11 received HLA-DR3-negative grafts. Only two HLA-
DR3-negative recipients received HLA-DR3-positive grafts, 
and both of these experienced at least one episode of rejection. 
Episodes of rejection occurred in three of eight patients who 
received HLA-8-positive grafts (Fig. 4). Two of these patients 
were negative for HLA-B8. Twenty-one of 35 recipients of 
HLA-B8-negative grafts experienced rejection. Nine of these 
were HLA-B8-negative. Thirteen of 21 HLA-B8-positive re-
cipients and 11 of 22 HLA-B8-negative recipients experienced 
at least one episode of rejection. 
DISCUSSION 
In this study, an attempt was made to elucidate the influence 
of donor/recipient matching or mismatching for HLA-B8 and 
DR3 antigenic determinants on subsequent episodes of rejec-
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FIGURE 2. Percentage of recipients experiencing disease recurrence 
based upon the HLA-B8 status of the donor-recipient pairing. 
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FIGURE 4. Percentage of reci~A experiencing graft rejection 
based upon the HLA-B8 status of the donor-recipient pairing. 
tion and disease recurrence in patients transplanted for 
ACALD. These antigens were chosen for study because they 
are known to be associated with autoimmune chronic active 
liver disease (2). All recipients transplanted for ACALD who 
survived for 10 months or more were studied. Their records 
were examined for episodes of graft rejection and histologic 
evidence of disease recurrence. The data available indicate that 
recipients who are HLA-DR3-positive and receive HLA-DR3-
negative donor organs are at increased risk to experience his-
tologic recurrence of ACALD. Although a similar trend was 
evident for recipients having the HLA-B8 antigen, the finding 
failed to achieve the level of statistical significance. 
It has been shown previously that the B8/DR3 phenotype is 
associated with a exaggerated humoral immune response (7), 
increased mixed leukocyte reactions (8), increased in vitro 
responses to wheat antigens (9), and decreased concanavalin 
A-induced suppression of immunoglobulin synthesis, along 
with an increased spontaneous in vitro Ig synthesis ( 10). N ouri-
Aria et a1. (11) have shown an association between the presence 
of HLA antigens A1/B8/DR3 in families of patients with 
autoimmune chronic active hepatitis and a defect in nonanti-
gen-specific suppressor T-cell control of immunoglobulin pro-
duction. Such pathogenetic mechanism(s) might playa role in 
the pathogenesis of ACALD and possibly disease recurrence 
should it occur. 
A major issue in this study was how certainly could we 
distinguish histologic disease recurrence in a liver graft as 
opposed to new-onset viral hepatitis. Immunoperoxidase stains 
for CMV and EBV were negative in all of the cases with 
putative disease recurrence. Similarly, all 11 cases were nega-
tive for hepatitis A, B, and D markers. The possibility of a non 
A, non B hepatitis (HCV) was ruled out also, with the use of 
the recently available HCV antibody assay developed by Abbott 
Laboratories. All 11 cases of histologic disease recurrence of 
ACALD were negative for HCV, despite the reports of false 
positive HCV-Ab responses in individuals with ACALD (12). 
The results of this study indicate an increased susceptibility 
to "recurrent autoimmune chronic hepatitis" characterized by 
piecemeal necrosis and a dense portal inflammatory infiltrate 
consisting of mature plasma cells and lymphocytes as opposed 
to immunoblasts in recipients who are HLA-DR3-positive. 
Moreover, the presence of any biliary tract lesion responsible 
for the histologic·findings was excluded by cholangiography in 
each case at the time of the disease recurrence defined histo-
logically. Moreover, these histologic findings suggestive of re-
current ACALD occurred in the absence of any evidence for 
viral hepatitis either before or after OLTx. 
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In contrast to these data suggesting disease recurrence, no 
difference in the rejection episode rate was evident among the 
various subgroups of transplant recipients assessed based upon 
the presence or absence of any HLA match or mismatch of the 
antigens studied. This latter finding confirms the earlier finding 
that HLA matching does not influence graft rejection rates in 
liver transplantation (4). 
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INJECTION OF XENOGENEIC ENDOCRINE PANCREATIC 
TISSUE INTO THE PORTAL VEIN-EFFECTS ON 
COAGULATION, LIVER FUNCTION, AND HEPATIC 
HEMODYNAMICS 
A STUDY IN THE PIG-TO-DOG MODELl 
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The safety of injecting discordant xenogeneic fetal 
endocrine pancreatic ti88ue into the portal vein was 
studied in a pig-to-dog system. It was found that minced 
fetal porcine pancreas and fetal porcine isletlike cell 
clusters prepared by collagenase digestion and culture 
could be injected with only minor or no hepatic hemo-
1 This work was supported by the Swedish Medical Research Council 
(l2X-109; 19X-520; 12P-8435; 19P-8982l, the Swedish Diabetes Asso-
ciation, the Juvenile Diabetes Federation International, the Nordic 
Insulin Fond, the Hoechet Diabetes Foundation, and the Marianne and 
Marcus Wallenberg Foundation. 
2 Address correspondence to: Jan Tollemar, M.D., Department of 
Transplantation Surgery, Huddinge HOBpitai, S-14186 Huddinge, Swe-
den. 
dynamic disturbances. Coagulation studies revealed a 
small increase in plasma fibrinopeptide A, but this in-
crease could be prevented by heparinization of the re-
cipient. There was no consumption of fibrinogen or 
platelets. In contrast, injection of minced adult porcine 
pancreas caused pronounced hepatic hemodynamic 
changes and marked coagulation abnormalities, indicat-
ing consumption coagulopathy. The present finding that 
fetal porcine pancreas can be injected intraportally 
without deleterious effects in dogs provides a foundation 
for the eventual clinical use of such material as treat-
ment for insulin-dependent diabetes mellitus. 
For several years, transplantation of islets of Langerhans has 
proved to be a successful means of curing diabetes in a variety 
